145,182 members

Skip to content. | Skip to navigation

News

NICE recommends another revolutionary CAR T-cell therapy for adults with lymphoma

 

Start sharing

If you've got news you'd like to share, let us know and we'll consider it for our news section.
 

NICE recommends another revolutionary CAR T-cell therapy for adults with lymphoma

Adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) will be able to access another revolutionary chimeric antigen receptor T-Cell (CAR T-cell) therapy through the cancer drugs fund.

Tisagenlecleucel, also known as Kymriah and made by Novartis, is recommended for adults with relapsed or refractory DLBCL. It will be offered to people whose disease has not responded or those whose disease has relapsed after treatment with two or more courses of chemotherapy.

Lymphomas are cancers of the lymphatic system which is part of the immune system. There were 11,690 new cases of non-Hodgkin lymphoma (NHL) in England in 2015 with 4,688 of these being diffuse large B-cell lymphoma.